Skip to main content

PerkinElmer Closes $300M Acquisition of Cord Stem-Cell Company ViaCell

NEW YORK (GenomeWeb News) — PerkinElmer said today it has closed the acquisition of ViaCell, an umbilical cord blood preservation business, for around $300 million, or $7.25 a share.
 
ViaCell collects and stores stem cells from newborns’ umbilical cords that might be of medical use by the child or a relative. PerkinElmer expects the company’s flagship ViaCord technology to complement its current prenatal screening tools for the risk of chromosomal abnormalities.
 
PerkinElmer, which first announced its plan to buy the company last month, reiterated its intent to continue selling and supporting ViaCord while divesting the ViaCell therapeutic business.
  
Sales of ViaCord in 2007 are expected to be around $60 million, PerkinElmer said.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.